glp-1 ckd Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes GLP-1 therapy CKD - Diabetes
Description
doi: 10.1001/jama.2021.1831
Improved blood sugar control (slower glucose spikes)
GLP-1 and GIP were also responsible for down-regulating the expression of MCP1, VCAM1, ICAM1 and PAI1molecules regulating inflammatory response
34 The trial had a total of 731 patients with a baseline mean A1C of 8.2% and a baseline total daily dose of insulin ranging from 56 to 62 units, depending on the treatment group
But they contribute almost nothing to muscle preservation, and the people who stall at week four on semaglutide often share this pattern
